Oncology Drug Reference Sheet: Fruquintinib

In two clinical trials, patients who received fruquintinib (Fruzaqla^™) had an overall survival of 7.4 and 9.3 months compared to 4.8 and 6.6 months with placebo, leading to the drug’s November 2023 U.S. Food and Drug Administration approval for adults with metastatic colorectal cancer who previously received standard chemotherapy and experienced disease progression.